Clinical Trials Logo

Dermatitis clinical trials

View clinical trials related to Dermatitis.

Filter by:

NCT ID: NCT03824405 Completed - Atopic Dermatitis Clinical Trials

Study of the Safety, Tolerability and Efficacy of BTX 1204 in Patients With Moderate Atopic Dermatitis

Start date: February 4, 2019
Phase: Phase 2
Study type: Interventional

This is a randomized, double-blind, vehicle-controlled, Phase 2 study in subjects with moderate AD.

NCT ID: NCT03822832 Completed - Dermatitis, Atopic Clinical Trials

A Study in Patients With Atopic Eczema to Test How Effective BI 655130 is and How Well it is Tolerated

Start date: February 12, 2019
Phase: Phase 2
Study type: Interventional

The primary objective of this trial is to investigate the safety, tolerability and efficacy of BI 655130 in patients with Atopic Dermatitis (AD) following repeated intravenous administrations compared to placebo.

NCT ID: NCT03813472 Completed - Atopic Dermatitis Clinical Trials

Hydration Sensor for Atopic Dermatitis

Start date: November 25, 2019
Phase:
Study type: Observational

Pilot study of a soft, flexible hydration sensor

NCT ID: NCT03807453 Completed - Clinical trials for Microbial Colonization

Comparison of Scalp Microbiota of the Psoriasis and Seborrheic Dermatitis Patients

Start date: April 25, 2019
Phase:
Study type: Observational

A sterile swap specimen taken from the scalp of the patients with psoriasis vulgaris or seborrheic dermatitis and the volunteer control group will be examined in our study. The examples of the microbiota of the patients will be taken both the lesional scalp and the lesion-free part of the scalp. Then, the microbiota differences between the lesioned scalp and the lesion-free scalp of both groups, and the microbiome differences between the two groups and the control group will be evaluated.

NCT ID: NCT03798561 Completed - Dermatitis, Atopic Clinical Trials

Study to Evaluate ASN008 Topical Gel (TG)

Start date: January 14, 2019
Phase: Phase 1
Study type: Interventional

This is an ascending dose escalation study to test the safety, tolerability and preliminary efficacy of ASN008 TG in first-in-human subjects

NCT ID: NCT03796676 Completed - Atopic Dermatitis Clinical Trials

JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis

JADE TEEN
Start date: February 18, 2019
Phase: Phase 3
Study type: Interventional

This is a randomized, double blind, placebo controlled, parallel group, Phase 3 study to evaluate the efficacy and safety of PF 04965842 in adolescent participants 12 to <18 years of age with moderate to severe AD.

NCT ID: NCT03779360 Completed - Inflammation; Skin Clinical Trials

Intradermal LPS and Antibiotics

Start date: October 12, 2018
Phase: N/A
Study type: Interventional

Erythromycin and clindamycin are believed to have anti-inflammatory aspects. This study investigates the possible anti-inflammatory effects of erythromycin and clindamycin.

NCT ID: NCT03775434 Completed - Atopic Dermatitis Clinical Trials

A Study of B244 Delivered as a Topical Spray to Assess Safety in Pediatric Subjects With Atopic Dermatitis

Start date: December 7, 2018
Phase: Phase 1
Study type: Interventional

An open-label, multicenter, Phase Ib study of B244 delivered as a topical spray to assess safety in pediatric subjects aged 2 to 17 years with atopic dermatitis Condition or disease Intervention/treatment Phase Atopic Dermatitis (Eczema) Biological: B244 Phase 1b

NCT ID: NCT03770858 Completed - Atopic Dermatitis Clinical Trials

Wearable Skin Sensors to Assess Nocturnal Scratch Behavior

Start date: April 18, 2019
Phase:
Study type: Observational

Pilot study of flexible and wearable sensor to monitor nocturnal scratching behavior

NCT ID: NCT03761537 Completed - Atopic Dermatitis Clinical Trials

Tralokinumab in Combination With Topical Corticosteroids in Subjects With Severe Atopic Dermatitis - ECZTRA 7

ECZTRA 7
Start date: December 13, 2018
Phase: Phase 3
Study type: Interventional

Primary objective: To demonstrate that tralokinumab in combination with topical corticosteroids (TCS) is superior to placebo in combination with TCS in treating severe AD in subjects who are not adequately controlled with or have contraindications to oral cyclosporine A (CSA). Secondary objectives: To evaluate the efficacy of tralokinumab in combination with TCS on severity and extent of AD, itch, and health-related quality of life compared to placebo in combination with TCS. To evaluate the safety of tralokinumab in combination with TCS when treating severe AD in subjects who are not adequately controlled with or have contraindications to oral CSA compared to placebo in combination with TCS.